Wexford Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Wexford Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-12,600	Closed	-$351K	–	142
2017 Q2	$351K	Buy	+12,600	New	+$376K	0.03%	136
2016 Q4	–	Sell	-31,100	Closed	-$989K	–	250
2016 Q3	$989K	Buy	+31,100	New	+$1.05M	0.16%	99
2015 Q4	–	Sell	-14,815	Closed	-$490K	–	63
2015 Q3	$490K	Hold	14,815	–	–	0.09%	73
2015 Q2	$620K	Hold	14,815	–	–	0.17%	51
2015 Q1	$483K	Buy	+14,815	New	+$509K	0.14%	55
2014 Q2	–	Sell	-182,871	Closed	-$4.45M	–	113
2014 Q1	$4.45M	Buy	+182,871	New	+$4.63M	0.34%	44

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wexford Capital's ACAD Position: Q3 2017 in Review

Wexford Capital sold out of Acadia Pharmaceuticals (ACAD) in Q3 2017, closing a stake of 12,600 shares — an estimated $351K sold.

Wexford Capital first reported a position in ACAD in Q1 2014 and held it in 6 quarters. The position peaked at $4.45M in Q1 2014. 212 funds tracked by Wall St. Rank hold ACAD as of Q3 2017.

Wexford Capital reported no remaining Acadia Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Wexford Capital sold 12,600 Acadia Pharmaceuticals shares in Q3 2017, an estimated $351K.
Wexford Capital first reported a position in Acadia Pharmaceuticals in Q1 2014 and held it in 6 quarters.
Wexford Capital's Acadia Pharmaceuticals position peaked at $4.45M in Q1 2014.
212 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2017.

Based on Wexford Capital's 13F filing for Q3 2017, filed 13 Nov 2017.